ProQR Therapeutics N.V. (PRQR)

1,9400 -0,0200 (-1,02%) Alla chiusura: 04:00PM EDT

ProQR Therapeutics N.V.

Zernikedreef 9
Leiden 2333 CK
Netherlands
31 88 166 7000
https://www.proqr.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 156

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Domenico Valerio Ph.D.	Founder & Independent Chairman of Supervisory Board	79,17k	N/D	1956
Mr. Daniel Anton de Boer	Founder, CEO & Member of Management Board	1,28M	N/D	1983
Mr. Rene K. Beukema	Chief Corporate Development Officer, General Counsel & Member of Management Board	978,96k	N/D	1964
Dr. Gerard Platenburg	Co-Founder & Chief Scientific Officer	23,54k	N/D	1964
Mr. Jurriaan Dekkers	Chief Financial Officer	N/D	N/D	1976
Ms. Sheila Sponselee	Chief People & Operations Officer	N/D	N/D	1984
Ms. Sarah Cue Kiely	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Sandra van der Kolk	Junior Financial Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Governance aziendale

L'ISS Governance QualityScore di ProQR Therapeutics N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.